File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine

TitleTreatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine
Authors
Issue Date2017
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/issn/0268960X
Citation
Blood Reviews, 2017 How to Cite?
AbstractInformation arising from next generation sequencing of leukemia genome has shed important light on the heterogeneous and combinatorial driver events in acute myeloid leukemia (AML). It has also provided insight into its intricate signaling pathways operative in the disease pathogenesis. These have also become biomarkers and targets for therapeutic intervention. Emerging evidence from in vitro drug screening has demonstrated its potential value in predicting clinical drug responses in specific AML subtypes. However, the best culture conditions and readouts have yet to be standardized and the drugs included in these screening exercises frequently revised in view of the rapid emergence of new therapeutic agents in the oncology field. Testing of leukemia cell functions, including BCL2 profiling, has also been used to predict treatment response to conventional chemotherapy and hypomethylating agents as well as BCL2 antagonist in small patient cohorts. These platforms should be integrated into future clinical trials to develop personalized treatment of AML.
Persistent Identifierhttp://hdl.handle.net/10722/245107
ISSN
2015 Impact Factor: 6.627
2015 SCImago Journal Rankings: 2.841

 

DC FieldValueLanguage
dc.contributor.authorLam, SY-
dc.contributor.authorHe, BA-
dc.contributor.authorLeung, AYH-
dc.date.accessioned2017-09-18T02:04:44Z-
dc.date.available2017-09-18T02:04:44Z-
dc.date.issued2017-
dc.identifier.citationBlood Reviews, 2017-
dc.identifier.issn0268-960X-
dc.identifier.urihttp://hdl.handle.net/10722/245107-
dc.description.abstractInformation arising from next generation sequencing of leukemia genome has shed important light on the heterogeneous and combinatorial driver events in acute myeloid leukemia (AML). It has also provided insight into its intricate signaling pathways operative in the disease pathogenesis. These have also become biomarkers and targets for therapeutic intervention. Emerging evidence from in vitro drug screening has demonstrated its potential value in predicting clinical drug responses in specific AML subtypes. However, the best culture conditions and readouts have yet to be standardized and the drugs included in these screening exercises frequently revised in view of the rapid emergence of new therapeutic agents in the oncology field. Testing of leukemia cell functions, including BCL2 profiling, has also been used to predict treatment response to conventional chemotherapy and hypomethylating agents as well as BCL2 antagonist in small patient cohorts. These platforms should be integrated into future clinical trials to develop personalized treatment of AML.-
dc.languageeng-
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/issn/0268960X-
dc.relation.ispartofBlood Reviews-
dc.rightsPosting accepted manuscript (postprint): © <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleTreatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine-
dc.typeArticle-
dc.identifier.emailHe, BA: alexhe@hku.hk-
dc.identifier.emailLeung, AYH: ayhleung@hku.hk-
dc.identifier.authorityLeung, AYH=rp00265-
dc.identifier.doi10.1016/j.blre.2017.08.001-
dc.identifier.hkuros275923-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats